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Impact of comorbid asthma 
on severity of coronavirus disease 
(COVID‑19)
Sang Chul Lee1,5, Kang Ju Son2,3,5, Chang Hoon Han1, Ji Ye Jung4,6* & Seon Cheol Park1,6*
The severity of the coronavirus disease (COVID‑19) is associated with various comorbidities. However, 
no studies have yet demonstrated the potential risk of respiratory failure and mortality in COVID‑19 
patients with pre‑existing asthma. We selected 7272 adult COVID‑19 patients from the Korean Health 
Insurance Review and Assessment COVID‑19 database for this nationwide retrospective cohort study. 
Among these, 686 patients with asthma were assessed by their severities and evaluated by the clinical 
outcome of COVID‑19 compared to patients without asthma. Of 7272 adult COVID‑19 patients, 686 
with asthma and 6586 without asthma were compared. Asthma was not a significant risk factor for 
respiratory failure or mortality among all COVID‑19 patients (odds ratio [OR] = 0.99, P = 0.997 and 
OR = 1.06, P = 0.759) after adjusting for age, sex, and the Charlson comorbidity score. However, a 
history of acute exacerbation (OR = 2.63, P = 0.043) was significant risk factors for death among COVID‑
19 patients with asthma. Asthma is not a risk factor for poor prognosis of COVID‑19. However, asthma 
patients who had any experience of acute exacerbation in the previous year before COVID‑19 showed 
higher COVID‑19‑related mortality, especially in case of old age and male sex.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of the coronavirus 
disease (COVID-19) outbreak in Wuhan, China, on January 9, 2020. Since the World Health Organization 
declared COVID-19 a pandemic, the number of cases has increased at an exponential rate. To date, there have 
been 19,369,210 confirmed cases around the world with 732,499  deaths1.
This novel single-stranded enveloped ribonucleic acid virus is the seventh known human coronavirus. It 
belongs to the same family that causes severe acute respiratory syndrome (SARS) and Middle East respiratory 
syndrome (MERS), which are transmitted through similar zoonoses. Although the virologic characteristics of 
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SARS-CoV-2 are similar to those of MERS and SARS, it is highly contagious compared to  them2,3. Symptoms 
of COVID-19 range from mild upper respiratory infections to severe pneumonia and death because of acute 
respiratory failure. To date, various host factors, such as old age, smoking, and comorbidities, are relevant to 
the prognosis of COVID-194–6. In particular, the prognosis of patients with chronic obstructive pulmonary 
disease (COPD) is poor, and a promising mechanism by increased gene expression of angiotensin-converting 
enzyme 2 (ACE2) in the small airway epithelium has been  explained7.
In addition to COPD, asthma is a major chronic airway disease, and its prevalence has been increasing 
worldwide since  19508,9. More than 300 million people worldwide, including 25 million Americans, are affected 
by asthma. Asthma is a heterogeneous clinical syndrome that includes bronchial hyperresponsiveness, airway 
inflammation, and variable expiratory airflow  limitation10. Generally, acute exacerbations of asthma following 
pneumonia can increase emergency room visits and admission rates, which could lead to poor outcomes, such 
as respiratory failure or death. Moreover, patients with severe asthma are exposed to prolonged, high-dose sys-
temic corticosteroids, which could increase the mortality by developing systemic diseases, such as hypertension, 
diabetes, osteoporosis, and impaired humoral  immunity11,12.
Since the emergence of COVID-19, scientists worldwide have been trying to understand the clinical, diagnos-
tic, and prognostic aspects of the disease. However, no studies have been conducted on the prognostic outcomes 
in COVID-19 patients with pre-existing asthma. Therefore, this study analyzed the impact of asthma on the 
morbidities and mortalities of COVID-19 patients.
Materials and methods
Data source. In this study, we evaluated nationwide data regarding the clinical outcomes of COVID-19 in 
Korea between January 20 (diagnosis date of the first confirmed case) and May 27, 2020 using the administra-
tive claims database of the Health Insurance Review and Assessment (HIRA) in South Korea. Since Korea has a 
national health insurance service, which provides universal coverage for almost every Korean citizens, HIRA has 
fully adjudicated medical and pharmacy claims for COVID-19 patients. The database of HIRA contains general 
demographic data, the 10th revision of the International Statistical Classification of Diseases and Related Health 
Problems (ICD-10), medications prescribed, and medical  cost13.
Study design. We conducted a retrospective cohort study in South Korea to assess the risk factors of res-
piratory failure or mortality in COVID-19 patients with asthma. The patients with COVID-19 were defined 
by the following diagnostic codes using the HIRA dataset: B342, B972, B18, U181, and U071. All diagnoses 
were confirmed by reverse transcription-polymerase chain reaction testing for SARS-CoV-2. From the initial 
screening to the evaluation of the clinical outcomes of COVID-19 patients, the study period was divided into 
the following three different periods: 1. the premeasurement period, 2. measurement period, 3. the COVID-19 
period (Fig. 1). During the premeasurement period (January 1–December 31, 2018), the inclusion and exclu-
sion criteria were adapted among the adult COVID-19 patients. Variables associated with patient characteristics 
Figure 1.  Study scheme. Information on the study population was collected from three different periods: 
the premeasurement period, measurement period, and coronavirus disease (COVID-19) period. The 
inclusion and exclusion criteria were adapted, and baseline characteristics of patients were assessed during the 
premeasurement period. Asthma severity, number of acute exacerbation(s), and medication possession ratio 
were evaluated during the measurement period. COVID-related morbidities and mortalities were evaluated 
during the COVID-19 period. COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory 
syndrome coronavirus 2; ICD-10, 10th revision of the International Statistical Classification of Diseases and 
Related Health Problems; MPR, medication possession ratio; ICU, intensive care unit.
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were also assessed during this period. Asthma severity, number of acute exacerbations, and drug adherence were 
measured 1 year after the premeasurement period (measurement period: January 1–December 31, 2019). After 
confirmed cases of COVID-19 were identified, morbidities and mortalities were evaluated. To better identify the 
impact of asthma, other respiratory ailments, such as COPD, bronchiectasis, and interstitial lung disease, were 
not included in this study.
Case identification. Within the HIRA database, 7590 confirmed cases of COVID-19 were initially screened. 
Among them, 7272 confirmed COVID-19 patients aged ≥ 20 years were finally included, and they were divided 
into the asthma and non-asthma groups. Asthma patients were identified based on diagnostic and treatment 
evidence. All asthma cases were included when both diagnostic codes (primary or secondary diagnostic code for 
asthma: J45.x, J46.x) and medication codes were simultaneously identified more than twice during the premeas-
urement period. Medication codes for inhaled corticosteroids (ICSs), inhaled long-acting β2-agonists (LABA 
inhalers), inhaled long-acting muscarinic antagonists (LAMA inhalers), fixed-dose combinations, such as ICS/
LABA inhalers, oral β2-agonists, leukotriene antagonists, mast cell stabilizers, xanthine derivatives, and systemic 
corticosteroids, were used to evaluate medication use for asthma. Cases in which patients were under 20 years of 
age or those with an observation period of less than 1 year were excluded. Subsequently, 686 COVID-19 patients 
with asthma were compared with 6586 COVID-19 patients without asthma.
Charlson comorbidity index. The Charlson comorbidity index (CCI) is a widely used prognostic model 
that predicts 1-year mortality risk depending on the individual severity of comorbidities. The necessary infor-
mation to calculate the CCI was obtained through the diagnostic codes obtained during the premeasurement 
period. Then, the CCI was calculated by the summation of the scores of each comorbidity, as shown in Sup-
plementary Table 1. We adapted and analyzed the CCI as a variable because it was suitable for measuring the 
impact of comorbidities on mortality using the health care administrative database, including ICD-10  codes14,15.
Assessment of asthma severity. During the measurement period, asthma severity was assessed based 
on the patient’s medication use according to the guidelines from the Global Initiatives for Asthma (GINA)10. 
Although the stepwise approach with dose modification of ICS or oral asthma medication(s) is the backbone of 
asthma treatment, there is a limitation in clearly distinguishing the precise dosage of ICS or ICS/LABA in the 
administrative claims database of HIRA. Hence, previous studies suggested a new definition of asthma severity 
to analyze the claims  data16,17. According to the prescribed medication(s) during the premeasurement period, 
asthma severity was classified into three exclusive categories: mild, moderate, and severe. Asthma severity was 
defined as “mild” if the patient was prescribed at least one asthma medication, excluding ICS/LABA inhalers, 
low-dose systemic corticosteroids (defined as a prednisolone equivalent of < 10 mg/day for at least 2 weeks), 
and tiotropium. Asthma severity was defined as “moderate” if a patient was prescribed a low-dose or high-dose 
ICS/LABA inhaler, but not tiotropium or low-dose oral corticosteroids (OCSs). Asthma severity was defined as 
“severe” if a patient was prescribed an ICS/LABA inhaler and received at least one prescription of tiotropium or 
a low-dose OCS.
Definition of acute exacerbation and medication possession ratio. Acute exacerbation was 
defined as the presence of primary or secondary diagnostic code for asthma (J45.x, J46.x), along with any of the 
following: (1) high-dose systemic corticosteroid use (≥ 30 mg, over 3 days consecutively), (2) hospitalization, or 
(3) emergency room visit. To measure the drug adherence for asthma medications, medication possession ratio 
(MPR) was  used18,19. The MPR was calculated as the sum of the day’s supply for all medications, and divided by 
the time from first fill until the end of the measurement  period20. Subsequently, patients were categorized into 
three adherence groups as follows: low (MPR < 50%), medium (MPR 50% to 80%), and high (MPR > 80%)21. 
Asthma medications, such as ICSs, LABA or LAMA inhalers, ICS/LABA inhalers, oral β2-agonists, leukotriene 
antagonists, mast cell stabilizers, xanthine derivatives, and systemic corticosteroids, were used to measure the 
MPR status.
Clinical outcome and severity of COVID‑19. The primary outcome was respiratory failure and mor-
tality among COVID-19 patients. Cases of mechanical ventilation or extracorporeal membrane oxygenation 
(ECMO) were defined as patients who experienced respiratory failure. Other clinical outcomes, such as length 
of hospital stay, overall medical expenses, number of intensive care unit (ICU) care cases, and length of ICU care, 
were also evaluated. Depending on the clinical outcomes, study subjects were divided into two groups: severe 
and non-severe groups. Patients who had history of ICU care, mechanical ventilation, ECMO, or death, were 
classified as severe group. All other COVID-19 patients were classified as non-severe group.
Statistical analyses. The baseline characteristics of each group were compared using the paired t-test and 
chi-square analysis. Subsequently, multivariate logistic regression analysis was performed to evaluate the asso-
ciation between the risk factors and COVID-19-related outcomes and was reported as adjusted odds ratio (OR) 
with 95% confidence interval (CI). Two models were used to assess the risk of respiratory failure and death, one 
analyzing the asthma group and the other analyzing moderate to severe asthma group as risk factors. All data 
transformations and statistical analyses were conducted using the Statistical Analysis System software V9.4 for 
Windows (SAS Institute, Cary, NC, USA). And all tests were two-sided, with a significance level of 0.05.
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Ethics approval. This study was approved by the Institutional Review Board of the National Health Insur-
ance Service Ilsan Hospital and adhered to the tenets of the Declaration of Helsinki (NHIMC 2020-04-010). The 
requirement for informed consent was waived by Institutional Review Board of the National Health Insurance 
Service Ilsan Hospital because of the retrospective nature of this study. All personal identifying information of 
the study individuals was anonymous.
Ethical declarations. This article does not contain any studies with human or animal subjects performed 
by any of the authors.
Results
Patient characteristics. Of the total 7272 COVID-19 patients, 686 (9.4%) patients with asthma and 6586 
(90.6%) without asthma were compared. Among the patients with asthma, 614 (89.5%), 64 (9.3%), and 8 (1.1%) 
were classified as “mild,” “moderate,” and “severe,” respectively (Fig.  2). Baseline demographics of the study 
population are shown in Table 1. The asthma group predominantly consisted of elderly patients over 60 years 
of age (43.8%), and a large number of young patients under 40 years of age (37.7%) was included in the non-
asthma group. In both the groups, the number of more women was more than men (64.0% in asthma and 59.4% 
in non-asthma groups). In the asthma group, all comorbidities were observed more frequently, and the CCI 
score. When asthma severity was compared, the moderate to severe group showed a higher proportion of older 
patients and higher CCI score than the mild group. Additionally, the moderate to severe group showed a higher 
proportion of patients with medium to high MPR and more frequent history of acute exacerbation than the mild 
group.
COVID‑19‑related morbidities and mortalities. COVID-19-related medical costs were higher in the 
asthma group than in the non-asthma group (5488.4 United states dollar [USD] vs. 4410.1 USD, P < 0.001) 
(Table  2). Although there was no difference in the hospitalization rates between the two groups, the length 
Table 1.  Patient characteristics. Data are presented as numbers (%) or means ± standard deviations. IHD, 
ischemic heart disease; CCI, Charlson comorbidity index; MPR, medication possession ratio. *P-value for 













Age (years)  < 0.001 0.002
20–39 2488 (37.7) 173 (25.3) 164 (26.7) 10 (13.8)
40–59 2267 (34.4) 211 (30.7) 194 (31.6) 17 (23.6)
≥ 60 1831 (27.8) 301 (43.8) 256 (41.6) 45 (62.5)
Sex, male 2680 (40.6) 247 (36.0) 0.017 215 (35.0) 32 (44.4) 0.114
Comorbidities
Chronic rhinitis 2951 (44.8) 599 (87.3)  < 0.001 541 (88.1) 58 (80.5) 0.068
Hypertension 1193 (18.1) 208 (30.3)  < 0.001 183 (29.8) 25 (34.7) 0.390
Diabetes 863 (13.1) 178 (25.9)  < 0.001 155 (25.2) 23 (31.9) 0.219
Dyslipidemia 1640 (24.9) 272 (39.6)  < 0.001 233 (37.9) 39 (54.1) 0.007
IHD 248 (3.7) 66 (9.6)  < 0.001 57 (9.2) 9 (12.5) 0.381
Heart failure 110 (1.6) 44 (6.4)  < 0.001 39 (6.3) 5 (6.9) 0.846
Malignancies 239 (3.6) 44 (6.4)  < 0.001 36 (5.8) 8 (11.1) 0.085
CCI score  < 0.001 0.027
0 3828 (58.1) 0 (0.0) 0 (0.0) 0 (0.0)
1 1264 (19.1) 270 (39.3) 252 (41.0) 18 (25.0)
2 653 (9.9) 147 (21.4) 129 (21.0) 18 (25.0)
3 339 (5.1) 101 (14.7) 91 (14.8) 10 (13.8)
 ≥ 4 502 (7.6) 168 (24.4) 142 (23.1) 26 (36.1)
MPR group –  < 0.001
Low – 508 (81.6) 525 (85.5) 35 (48.6)
Medium – 30 (4.3) 23 (3.7) 7 (9.7)
High – 96 (13.9) 66 (10.7) 30 (41.6)
Number of acute exacerbations –  < 0.001
0 – 650 (94.7) 594 (96.7) 56 (77.7)
1 – 19 (2.7) 11 (1.7) 8 (11.1)
2 – 17 (2.4) 9 (1.4) 8 (11.1)
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of hospital stay was longer in the asthma group (24.0  days vs. 22.3  days, P = 0.01). According to the sever-
ity classification, proportion of severe COVID-19 cases who showed severe clinical outcomes including ICU 
care, application of mechanical ventilation or ECMO, and death were higher in asthma group (9.1% vs. 4.6%, 
P < 0.001). In asthma patients, there was no significant difference of COVID-19 severity depending on asthma 
severity. In detail, ICU care rates in the asthma group were significantly higher (3.9% vs. 2.4%, P = 0.022) than in 
the non-asthma group. Among them, mechanical ventilation or ECMO, which indicated respiratory failure, was 
also frequent in the asthma group. In addition, the overall mortality rate was significantly higher in the asthma 
group (6.4% vs. 2.7%, P < 0.001). Among the asthma severity groups, patients with moderate to severe asthma 
had higher medical expenses than the mild asthma group during COVID-19 treatment (6577.4 USD vs. 5360.6 
USD, P < 0.001). The proportion of deaths was also significantly higher in the moderate to severe asthma group 
than in the mild asthma group (13.8% vs. 5.5%, P = 0.006).
Figure 2.  Flowchart of the study population. A total of 7590 coronavirus disease (COVID-19) patients were 
identified using the 10th revision of the International Statistical Classification of Diseases and Related Health 
Problems (ICD-10) diagnosis code. Among 7272 adult patients ≥ 20 years of age, 686 patients with asthma were 
identified using the ICD-10 code and medication use for asthma. Severity of asthma was classified according to 
the type of medication prescribed. COVID-19, coronavirus disease.
Table 2.  Clinical outcomes of coronavirus disease between asthma and non-asthma groups. Data are 
presented as numbers (%) or means ± standard deviations. *P-value for comparison between asthma and non-
asthma groups. † P-value for comparison between mild and moderate-severe groups. COVID-19, coronavirus 












COVID-19-related medical cost 
(USD) 4410.1 ± 5560.4 5488.4 ± 8412.9  < 0.001 5360.6 ± 7062.1 6577.4 ± 16,720.7  < 0.001
Admission 6169 (93.6) 642 (93.5) 0.932 575 (93.6) 67 (93.0) 0.846
Length of stay 22.3 ± 13.4 24.0 ± 15.4 0.010 23.7 ± 15.3 25.8 ± 15.8 0.312
COVID-19 severity  < 0.001 0.143
Non-severe 6278 (95.3) 623 (90.8) 561 (91.3) 62 (86.1)
Severe 308 (4.6) 63 (9.1) 53 (8.6) 10 (13.8)
ICU care 163 (2.4) 27 (3.9) 0.022 25 (4.0) 2 (2.7) 0.593
Length of stay 10.7 ± 9.1 9.8 ± 7.6 0.626 10.1 ± 7.8 6.5 ± 5.9 0.531
Application of mechanical ventila-
tion 99 (1.5) 19 (2.7) 0.012 17 (2.7) 2 (2.7) 0.996
Application of ECMO 15 (0.2) 6 (0.8) 0.002 5 (0.8) 1 (1.3) 0.620
Death 183 (2.7) 44 (6.4)  < 0.001 34 (5.5) 10 (13.8) 0.006
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Risk factors for respiratory failure and mortality in total COVID‑19 patients. Age (OR = 1.06, 
P < 0.001 and OR = 1.12, P < 0.001), male sex (OR = 2.31, P < 0.001 and OR = 2.46, P < 0.001), and the CCI score 
(OR = 1.13, P = 0.001 and OR = 1.18, P < 0.001) were identified as independent risk factors for respiratory failure 
and death in COVID-19 patients. Asthma was not a risk factor for respiratory failure or death, but moder-
ate to severe asthma showed a non-significant high risk of death (OR = 1.98, P = 0.065) (Table 3). Multivariate 
analysis using separate comorbidities instead of CCI score showed that diabetes and heart failure were inde-
pendent risk factors for mortality (OR = 2.02, P < 0.001 and OR = 1.98, P = 0.127; respectively) (Supplementary 
Table 2). Among the patients with asthma, age was a significant risk factor for both respiratory failure and death 
(OR = 1.05, P < 0.001 and OR = 1.10, P < 0.001, respectively). Additionally, male sex (OR = 2.26, P = 0.021) and 
a history of acute exacerbation of asthma within 1 year (OR = 2.63, P = 0.043) of COVID-19 infection showed 
increased mortality (Table 4).
Discussion
Currently, there is a lack of studies on the prognostic outcomes in COVID-19 patients with pre-existing asthma. 
Recently, several studies have suggested possible non-harmful effects of asthma on the clinical outcomes of 
COVID-19. A retrospective study by Zhao et al. evaluated the risk factors among 548 COVID-19 inpatients in 
Wuhan and reported that there were few patients with asthma and the risk was consistent with severe COVID-
19  cases22. A subsequent epidemiological study and literature review also supported that the comorbidity rates 
of asthma were significantly lower than the reported prevalence of asthma in the respective  regions23. However, 
the proportion of asthma patients among the total COVID-19 patients in our study was 9.4%, which is relatively 
higher than the previously known prevalence in Asian-Pacific  countries24,25. This prevalence was similar to other 
studies in the USA or UK, which also showed high comorbidity rates of asthma (12.5% and 14%, respectively)26,27. 
Previously, Park et al. demonstrated that elderly and female patients showed a higher prevalence of  asthma28. 
Hence, the comorbidity rate of asthma could be variable according to the composition of the study population. In 
South Korea, there was a large cluster of COVID-19 infection within a certain religious group, which comprised 
of twice the number of women worshippers than  men29. The number of transmissions linked to this religious 
facility was over half of the total COVID-19 patients (4363; 59.9%) in South Korea. However, unfortunately, 
detailed information about transmission during this religious meeting was not well known because of the secret 
property. In addition, susceptibility to infectious diseases could be considered. Men are generally more suscep-
tible to infection with diverse pathogens than  women30,31. Though, there is also evidence that women are more 
susceptible to infectious diseases, which could possibly explain why the number of women patients in this study 
was higher than that of  men32,33. Therefore, a large number of women were included in our study, which could 
have increased the proportion of asthma patients.
Table 3.  Multivariate analyses of risk factors associated respiratory failure and mortality among total study 
population. OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity score. a Adjusted for age, sex 
(male), and CCI.
Variable
Respiratory failure risk Mortality
Adjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Model 1
Age 1.06 (1.05–1.07)  < 0.001 1.12 (1.11–1.14)  < 0.001
Sex, male 2.31 (1.58–3.37)  < 0.001 2.46 (1.82–3.33)  < 0.001
CCI 1.13 (1.05–1.23) 0.001 1.18 (1.11–1.25)  < 0.001
Asthma 0.99 (0.58–1.70) 0.997 1.06 (0.71–1.59) 0.759
Model 2a
Moderate-severe asthma 0.66 (0.15–2.82) 0.581 1.71 (0.78–3.73) 0.173
Table 4.  Multivariate analyses of risk factors associated mortality in patients with asthma. OR, odds ratio; CI, 
confidence interval; MPR, medication possession ratio.
Variable
Respiratory failure risk Mortality
Adjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Age 1.05 (1.02–1.08)  < 0.001 1.10 (1.07–1.14)  < 0.001
Sex, male 1.00 (0.38–2.62) 0.985 2.26 (1.12–4.54) 0.021
Severity
Mild 1 (Reference) 1 (Reference)
Moderate-severe 0.81 (0.17–3.76) 0.795 1.33 (0.54–3.30) 0.526
Number of acute exacerbation(s)
0 1 (Reference) 1 (Reference)
 ≥ 1 0.42 (0.05–3.58) 0.432 2.63 (1.02–6.72) 0.043
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Compared to the non-asthma group, asthma group showed a larger amount of COVID-19-related medical 
expenses and higher proportion of respiratory failure, which led to the application of mechanical ventilation or 
ECMO. Because the median age and number of comorbidities were higher in the asthma group, the length of 
stay and frequencies of ICU admission were also high, which could contribute to the increased medical costs. 
However, multivariate analysis showed that asthma was not a significant risk factor for respiratory failure and 
death in COVID-19. Analysis after excluding the patients with mild asthma, even if there was an increasing 
tendency of OR in mortality, showed no statistical significance in patients with moderate to severe asthma. As 
we adapted an operative definition to distinguish asthma severity, relatively mild symptomatic patients could 
have been included in the moderate group. A small number of patients with moderate to severe asthma could 
also be the reason of this non-significance.
In addition, the role of ACE2 should be addressed to explain the relationship between asthma and COVID-19. 
The ACE2 receptor-binding domain is responsible for the first-stage host cell entry of the novel  coronavirus34,35. 
Many studies have demonstrated the upregulation of the ACE2 receptor in current smokers with  COPD36,37. 
Studies about the association between asthma and ACE2 expression are scarce; however, there are several studies 
on reduced ACE2 expression by type 2 inflammatory processes, which could lead to a decreased susceptibility 
to  infection22,23,38,39. These studies suggested that the expression of ACE2 is likely to be regulated reciprocally by 
interferons and Type 2 cytokines, especially in allergic asthma. This could explain why asthma was not associated 
with poor outcomes, including respiratory failure and death.
In contrast, among the asthma patients, age, male sex, and a history of acute exacerbation were revealed as 
significant risk factors for mortality. Patients with a history of acute exacerbation of asthma during the previous 
year had a more than twofold higher risk of mortality than the patients without any exacerbation history. The 
current status of asthma control could impact future exacerbation and vice  versa40,41. Moreover, acute exacer-
bations often lead to emergency room visits or hospitalization, which could increase the risk of COVID-19. 
Therefore, asthma patients with a recent exacerbation history should be considered as high-risk patients with 
poor prognostic outcome for COVID-19.
Although CCI was not an independent risk factor for poor prognostic outcomes, the diabetes significantly 
increased COVID-19 related mortality by twofolds of risk in consistent with other  studies42,43. It is not yet known 
whether people with diabetes are more susceptible to COVID-19, but several studies have reported a greater 
risk of severe COVID-19 in diabetic patients. Dysfunctional and pro-inflammatory cytokine responses, such as 
elevation of IL-1, IL-6, and tumor necrosis factor-α, are thought to be the possible  reason44–46.
Recently, two studies about asthma patients with COVID-19 in South Korea using HIRA database were 
published. Yang et al. analyzed entire cohort who underwent COVID-19 testing and reported that non-allergic 
asthma patients showed greater risk of susceptibility to COVID-19 infection and severe clinical outcomes of 
COVID-19, such as ICU admission, application of mechanical ventilation, or  death47. Because they extracted 
asthma patients with ICD-10 codes only, study population could have included those without pure asthma 
comorbidity. In addition, Choi et al. also reported higher mortality in asthma patients than in non-asthma 
patients among COVID-19  patients48. However, asthma itself and its severity showed no significant relationship 
with poor outcome of COVID-19. Compared to these studies, we have adopted operative definition for stratifi-
cation of unique asthma severity to overcome the limitation of medical claim database. Then, we demonstrated 
the clinical impact of recent exacerbation history of asthma on COVID-19 outcomes.
However, there were several limitations to this study. First, because of using administrative claims database, 
there is a potential for inaccuracies in coding and incompleteness of medical records. Moreover, information 
about smoking status, chest X-ray, and laboratory data were not available, so it was not possible to classify the 
severity of COVID-19 like previously reported guideline or  studies49–51. Second, there were differences of base-
line characteristics between asthmatics and non-asthmatics. Asthma group was older and showed higher CCI 
score, which could be the reason why asthma group showed significantly higher medical expenses and mortal-
ity although the multivariate analyses were conducted including age and CCI as covariates. Third, we used an 
operational definition to distinguish asthma severity, which may not fully reflect the current GINA steps. In 
our study, all patients who used an ICS/LABA inhaler were classified as moderate or higher regardless of the 
ICS dosage and frequency of inhaler use. Therefore, patients whose severity was GINA steps 2–4 could not be 
clearly distinguished. In addition, spirometry data, information on symptom variation (daytime or nocturnal 
symptoms), and optimal use of a controller or reliever inhaler, which are usually used to assess asthma control 
status, could not be measured in our study design. This may indicate that asthma severity with our operational 
definition could be underestimated compared to that of the GINA recommendation. Lastly, although systemic 
steroid use could be a risk factor for poor prognostic outcome, our study could not analyze it. The effect of sys-
temic steroid use and dose-dependent relationship with prognostic outcome should be evaluated in future stud-
ies. Fourth, we could not assess the atopic status of individual asthma patients. To evaluate the protective effect 
of T helper 2 cell-mediated inflammation on the ACE expression of the airway cells in clinical practice, further 
studies, including laboratory results, which could distinguish among the phenotypes of asthma, are needed.
Conclusions
Asthma itself is not a risk factor for poor prognosis of COVID-19. Elderly, males (only in asthma patients), or 
those who have multiple comorbidities need extra attention to avoid disease progression to respiratory failure or 
death. The mortality rate could be higher if the patients had experienced acute exacerbation in the previous year 
of COVID-19 infection, especially in case of old age and male sex. Therefore, special concerns for maintaining 
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